With new capital secured and the EMA’s acceptance of the CTA for uTREAT, Curasight is likely on track to deliver preliminary efficacy data from its ph1 trial in glioblastoma by Q4/25. We believe efficacy data have potential to be an inflection point for the shares. We update our SOTP-rNPV valuation range following the financing to DKK 14-36 (19-51) per share.
LÄS MER
